Skip to main content
Top

Cellular Oncology

Issue 1/2015

Personalized Cancer Genomics

Content (8 Articles)

Open Access Editorial

Personalized cancer medicine: next steps in the genomic era

S. Derks, B. Diosdado

Original Paper

Intrinsic cancer subtypes-next steps into personalized medicine

Cristina Santos, Rebeca Sanz-Pamplona, Ernest Nadal, Julieta Grasselli, Sonia Pernas, Rodrigo Dienstmann, Victor Moreno, Josep Tabernero, Ramon Salazar

Review

Long non-coding RNAs in cancer: implications for personalized therapy

Marianna Vitiello, Andrea Tuccoli, Laura Poliseno

Original Paper

We are all individuals… bioinformatics in the personalized medicine era

Leander Van Neste, Wim Van Criekinge

Review

Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care

Lemonitsa H. Mammatas, Henk M. W. Verheul, N. Harry Hendrikse, Maqsood Yaqub, Adriaan A. Lammertsma, C. Willemien Menke-van der Houven van Oordt

Review

Germline oncopharmacogenetics, a promising field in cancer therapy

Chiara Pesenti, Milena Gusella, Silvia M. Sirchia, Monica Miozzo

Erratum

Erratum to: Long non-coding RNAs in cancer: implications for personalized therapy

Marianna Vitiello, Andrea Tuccoli, Laura Poliseno

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine